scispace - formally typeset
Open AccessJournal ArticleDOI

Regulations and guidelines governing stem cell based products: Clinical considerations.

Bobby George
- 01 Jul 2011 - 
- Vol. 2, Iss: 3, pp 94-99
Reads0
Chats0
TLDR
This review summarizes the existing regulations/guidelines in US, EU, India, and the associated challenges in developing SCBP with emphasis on clinical aspects.
Abstract
The use of stem cells as medicines is a promising and upcoming area of research as they may be able to help the body to regenerate damaged or lost tissue in a host of diseases like Parkinson's, multiple sclerosis, heart disease, liver disease, spinal cord damage, cancer and many more. Translating basic stem cell research into routine therapies is a complex multi-step process which entails the challenge related to managing the expected therapeutic benefits with the potential risks while complying with the existing regulations and guidelines. While in the United States (US) and European Union (EU) regulations are in place, in India, we do not have a well-defined regulatory framework for "stem cell based products (SCBP)". There are several areas that need to be addressed as it is quite different from that of pharmaceuticals. These range from establishing batch consistency, product stability to product safety and efficacy through pre-clinical, clinical studies and marketing authorization. This review summarizes the existing regulations/guidelines in US, EU, India, and the associated challenges in developing SCBP with emphasis on clinical aspects.

read more

Citations
More filters
Journal ArticleDOI

Regenerative Skin Wound Healing in Mammals: State-of-the-Art on Growth Factor and Stem Cell Based Treatments.

TL;DR: The emerging field of regenerative skin wound healing in mammals is reviewed with particular emphasis on growth factor- and stem cell-based therapies.
Journal ArticleDOI

Insight on stem cell preconditioning and instructive biomaterials to enhance cell adhesion, retention, and engraftment for tissue repair.

TL;DR: This work describes how preconditioning of cells or cell manipulations strategies can enhance stem cell survival and engraftment after transplantation and discusses how biomaterials can enhance the function of stem cells for effective tissue regeneration.
Journal ArticleDOI

Cellular strategies to promote vascularisation in tissue engineering applications.

TL;DR: The authors provide an overview of the cellular strategies that can be used for increasing vascularisation in tissue engineering and regeneration and highlight the use of endothelial progenitor cells in co-culture systems.
Journal ArticleDOI

The potential impact of bone tissue engineering in the clinic

TL;DR: Current regenerative medicine and restorative strategies that utilize tissue engineering approaches to address bone defects within a clinical setting are discussed and a probable workpath for translation from the laboratory to the clinic is suggested.
Journal ArticleDOI

Improved Long-Term Volume Retention of Stromal Vascular Fraction Gel Grafting with Enhanced Angiogenesis and Adipogenesis.

TL;DR: Stromal vascular fraction gel has a high long-term retention rate and a unique adipose regeneration mode, involving prompt inflammation and infiltration of immune cells, stimulating rapid angiogenesis and inducing host cell–mediated adipogenesis.
References
More filters
Journal ArticleDOI

Mesenchymal Stem Cells: Revisiting History, Concepts, and Assays

TL;DR: The experimental origin of the concept of the population(s) referred to as mesenchymal stem cells and the experimental framework required to assess their stemness and function are revisited.
Journal ArticleDOI

Immunological reconstitution of sex-linked lymphopenic immunological deficiency

TL;DR: Treatment of a 5-month-old male with sex-linked lymphopenic immunological deficiency utilising immunologically competent cells from peripheral blood buffy coat and bone-marrow of a sibling donor resulted in reconstitution of both cellular and humoral immunity.
Journal ArticleDOI

FDA Regulation of Stem-Cell–Based Therapies

TL;DR: The authors review existing regulations regarding cell and tissue products and discuss how they expect the Food and Drug Administration to apply these regulations to scientists' efforts to develop and test stem-cell–based therapies.
Journal ArticleDOI

Challenges with advanced therapy medicinal products and how to meet them

TL;DR: The CAT discusses some of the typical issues raised by developers of ATMPs, and highlights the opportunities for such companies and research groups to approach the EMA and the CAT as a regulatory advisor during development.
Journal ArticleDOI

Off-label prescribing: a call for heightened professional and government oversight.

TL;DR: To exercise responsible self-regulation, members of the medical community must determine whether available evidence justifies specific off-label uses and must promote information-gathering when the evidence is inadequate.
Related Papers (5)